JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published In Press as doi:10.1074/jbc.M000439200 on March 16, 2000

J. Biol. Chem., Vol. 275, Issue 21, 15851-15860, May 26, 2000
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
275/21/15851    most recent
M000439200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Piluso, G.
Right arrow Articles by Nigro, V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Piluso, G.
Right arrow Articles by Nigro, V.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

gamma 1- and gamma 2-Syntrophins, Two Novel Dystrophin-binding Proteins Localized in Neuronal Cells*

Giulio PilusoDagger , Massimiliano Mirabella§, Enzo Ricci§||, Angela BelsitoDagger , Ciro AbbondanzaDagger , Serenella Servidei§, Annibale Alessandro PucaDagger **, Pietro Tonali§, Giovanni Alfredo PucaDagger , and Vincenzo NigroDagger Dagger Dagger

From the Dagger  Istituto di Patologia Generale ed Oncologia, Facoltà di Medicina, Seconda Università degli Studi di Napoli, 80138 Napoli, Italy, the § Istituto di Neurologia, Università Cattolica "A. Gemelli," Roma 00168, Italy, the  Center for Neuromuscular Diseases, Unione Italiana Lotta alla Distrofia Muscolare-Rome Section, Roma 00167, Italy, and the ** Division of Genetics, Children's Hospital, Boston, Massachusetts 02115

Received for publication, January 18, 2000, and in revised form, March 13, 2000

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Dystrophin is the scaffold of a protein complex, disrupted in inherited muscular dystrophies. At the last 3' terminus of the gene, a protein domain is encoded, where syntrophins are tightly bound. These are a family of cytoplasmic peripheral membrane proteins. Three genes have been described encoding one acidic (alpha 1) and two basic (beta 1 and beta 2) proteins of ~57-60 kDa. Here, we describe the characterization of two novel putative members of the syntrophin family, named gamma 1- and gamma 2-syntrophins. The human gamma 1-syntrophin gene is composed of 19 exons and encodes a brain-specific protein of 517 amino acids. The human gamma 2-syntrophin gene is composed of at least 17 exons, and its transcript is expressed in brain and, to a lesser degree, in other tissues. We mapped the gamma 1-syntrophin gene to human chromosome 8q11 and the gamma 2-syntrophin gene to chromosome 2p25. Yeast two-hybrid experiments and pull-down studies showed that both proteins can bind the C-terminal region of dystrophin and related proteins. We raised antibodies against these proteins and recognized expression in both rat and human central neurons, coincident with RNA in situ hybridization of adjacent sections. Our present findings suggest a differentiated role of a modified dystrophin-associated complex in the central nervous system.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Since the identification of dystrophin, the product of the Duchenne muscular dystrophy gene at Xp21, molecular genetics has moved quickly (1, 2). The deficiency of dystrophin in Duchenne muscular dystrophy (DMD)1 and its first animal model, the mdx mouse, leads to a dramatic reduction in a group of previously unknown proteins identified as the dystrophin-associated protein complex.

In the last few years, the dystrophin-associated protein complex proteins have been isolated; their genes have been cloned; and the following model of the complex has been hypothesized (3-5). Dystrophin is a large rod-shaped protein, primarily localized beneath the muscle cell membrane. Its actinin-like N terminus binds F-actin (6), whereas its C terminus is anchored to the transmembrane protein, beta -dystroglycan, which is linked through alpha -dystroglycan to the extracellular merosin (laminin-2) (7). Then, this complex bridges the muscle membrane from the cytoskeleton to the extracellular matrix. In addition, dystroglycan is the receptor for agrin, a protein with a pivotal role in the clustering of acetylcholine receptors at the neuromuscular junction (8-10) and a fundamental element of the basal lamina (11). At the muscle membrane, this complex is associated with the hydrophobic sarcospan DAP25 (dystrophin-associated protein; A5) (12) and the sarcoglycan complex, which is composed of at least four interacting transmembrane glycoproteins: alpha -sarcoglycan (DAG50 (dystrophin-associated glycoprotein), A2, adhalin) (13, 14), beta -sarcoglycan (DAG43, A3b) (15, 16), gamma -sarcoglycan (DAG35, A4) (17), and delta -sarcoglycan (18). Mutations in the laminin-alpha 2 gene are responsible for congenital muscular dystrophy (19); mutations in the gamma -, alpha -, beta -, and delta -sarcoglycan genes cause limb-girdle muscular dystrophies 2C, 2D, 2E, and 2F (13, 15-17, 20, 21), respectively; and mutations in the caveolin-3 gene cause a form of autosomal dominant limb-girdle muscular dystrophy (22, 23). In addition, animal models have been identified (24) or created by homologous recombination to establish the role of each component of the dystrophin-associated protein complex (25-28).

The extreme C terminus of dystrophin, which lies beneath the muscle membrane, is associated directly with a group of cytoplasmic peripheral membrane proteins known as syntrophins (29-34). A similar interaction has been demonstrated with utrophin, the autosomally encoded dystrophin-related protein (35), and with some dystrobrevin isoforms (36-38). The three known syntrophin isoforms, alpha 1, beta 1, and beta 2, are encoded by distinct genes with specific expression (33). alpha 1-Syntrophin is most abundant in skeletal muscle, where it is located close to the sarcolemma together with beta 1-syntrophin. In contrast, beta 2-syntrophin is largely concentrated at the neuromuscular junction, but is barely detectable at the sarcolemma. Syntrophins bind directly to the C-terminal domain of dystrophin, in the region encoded by exons 74 and 75 (34, 39-41). This region is contained in almost all mini-dystrophin transcripts starting from alternative distal promoters (42, 43). These shorter dystrophins, called apodystrophins or Dp, have nearly ubiquitous expression. Similar binding has been ascertained for a homologous region in utrophin and alpha - and beta -dystrobrevins (36, 38, 44, 45). In DMD, the sarcolemmal syntrophins are lost, whereas beta 2-syntrophin remains localized at the neuromuscular junction.

Each syntrophin has a characteristic domain organization in mammals (human, mouse, rabbit) as well as in the genetically distant Torpedo californica. Two pleckstrin homology (PH) domains and one PDZ domain are constantly present (46, 47), with the first PH domain split into two regions (PH1a and PH1b) by the PDZ domain and its flanking regions. In addition, another region has been recognized in the C-terminal 57 amino acids and termed the syntrophin unique (SU) domain (32, 33). There are indications that this domain may be directly involved in dystrophin binding. Here, we report the identification, through expressed sequence tag (EST) data base searching and cDNA library screening, of two novel human genes belonging to the syntrophin family.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Isolation of Human gamma 1- and gamma 2-Syntrophin cDNAs-- Approximately 500,000 plaques from a human fetal brain cDNA library in the lambda gt10 vector (CLONTECH) and the NT2 neuronal precursor cell cDNA library in the Uni-ZAP XR vector (Stratagene) were screened using EST clones 49263 and c-1gb01 (IMAGE Consortium) according to standard procedures (48). Sixteen positive clones (eight for each probe) were isolated. The open reading frames of gamma 1- and gamma 2-syntrophins were sequenced in at least two independent clones.

Northern Blotting-- Human total RNA and rat poly(A) RNA Northern blots were purchased from CLONTECH and Origene, respectively, and hybridized according to standard procedures (48). The 701- and 432-bp rat cDNA fragments, used as probes for gamma 1- and gamma 2-syntrophins, were obtained by RT-PCR using human-specific primer pairs.

PCR Conditions-- All PCR amplifications were performed in a PTC-100 thermal cycler (MJ Research, Inc.) as described previously (18).

Computational Analysis-- Multiple sequence alignment of proteins was realized using the CLUSTAL W1.7 program with default parameters (49). The alignment data were also utilized to obtain a phylogenetic tree of proteins. A prevision of secondary structure was obtained using the PHDsec algorithm (50). To search domains or functional sites in the sequences, we scanned PROFILE and PROSITE data bases using the ISREC web site.

Induction and Purification of Fusion Proteins-- The cDNAs encoding gamma 1-syntrophin (amino acids 195-302) and gamma 2-syntrophin (amino acids 209-299) as well as the corresponding regions of alpha 1-syntrophin (amino acids 173-505), beta 1-syntrophin (amino acids 205-351), and beta 2-syntrophin (amino acids 193-357) were cloned in frame with GST into the pGEX-2TK vector (Amersham Pharmacia Biotech), introduced into Escherichia coli JM109 cells, and induced using standard procedures.

The GST fusion proteins used in rabbit polyclonal antibody production (GST-gamma 1-syntrophin and GST-gamma 2-syntrophin) were purified using a continuous elution SDS-polyacrylamide gel electrophoresis apparatus (Model 491 Prep Cell, Bio-Rad), digested with thrombin protease (Amersham Pharmacia Biotech), and reloaded on the apparatus to separate GST from peptide. Protein concentration was determined (Bio-Rad protein assay).

For GST pull-down assay, cDNAs encoding dystrophin (amino acids 3194-3685), alpha -dystrobrevin (amino acids 422-564), and beta -dystrobrevin (amino acids 444-606) were cloned in frame with GST into the pGEX-2TK vector and introduced into E. coli JM109 cells. Twenty-ml overnight cultures were diluted 1:10 with LB medium supplemented with 1 mM 2-mercaptoethanol and 20 mM glucose. After induction with 0.1 mM isopropyl-beta -D-thiogalactopyranoside, cells were washed in PBS and resuspended in a 0.02 initial volume with 50 mM glucose, 25 mM Tris-HCl (pH 8.0), 10 mM EDTA, and 10 mg/ml lysozyme. After incubation for 10 min at room temperature (all following steps were carried out at 4 °C or on ice), an equal volume of 2× lysis buffer (final concentration: 50 mM Tris-HCl (pH 8.0), 200 mM NaCl, 1 mM EDTA, 1% Triton X-100, 1 mM phenylmethylsulfonyl fluoride, and protease inhibitors) was added, and cells were fractured with repeated cycles of freezing-thawing. The protein extract was clarified by centrifugation at 20,000 × g for 30 min and incubated with 100 µl of a 50% slurry of glutathione-agarose CL-4B (Fluka) for 2 h with shaking. After extensive washing in PBS supplemented with 1 mM phenylmethylsulfonyl fluoride and protease inhibitors, GST-dystrophin/dystrobrevin bead-bound fusion proteins was utilized in assay.

Antibody Production-- Anti-gamma 1- and anti-gamma 2-syntrophin antibodies were generated by subcutaneous injection of New Zealand White rabbits with 100 µg of purified gamma 1-syntrophin-(195-302) and gamma 2-syntrophin-(209-299) peptides, respectively, using the immunization protocol previously described (18). The antiserum titer (1:60,000 and 1:80,000, respectively) was determined by enzyme-linked immunosorbent assay, and specificity was verified by Western blotting.

Both antisera were affinity-purified on polyvinylidene difluoride membrane (Roche Molecular Biochemicals) blocked with purified GST-gamma 1-syntrophin-(195-302) and GST-gamma 2-syntrophin-(209-299) fusion proteins, respectively. Cyclic incubations of antiserum were followed by elution of affinity-purified antibodies with 100 mM glycine (pH 2.7), neutralized with Tris base at a final concentration of 25 mM at pH 7.8. For anti-gamma 1-syntrophin antiserum, a very weak cross-reactivity with alpha 1-syntrophin was eliminated by preincubation on polyvinylidene difluoride membrane blocked with purified GST-alpha 1-syntrophin-(173-505) fusion protein. Affinity-purified antibodies were concentrated using an Ultrafree-CL unit (Mr cutoff = 100,000; Millipore Corp.), supplemented with 3% bovine serum albumin and 0.5% NaN3, and stored at 4 °C.

Western Blotting-- Samples were run on 9% SDS-polyacrylamide gel and transferred to nitrocellulose sheets. Membranes were incubated for 2 h at room temperature with affinity-purified rabbit polyclonal antibodies diluted 1:1000 in Tris-buffered saline (50 mM Tris-HCl (pH 8.0) and 200 mM NaCl) with 0.5% nonfat milk, 0.05% Tween 20, and 0.05% Nonidet P-40. After washing, membranes were incubated for 1 h with peroxidase-conjugated anti-rabbit IgG diluted 1:10,000 in Tris-buffered saline with 0.5% nonfat milk, 0.05% Tween 20, and 0.05% Nonidet P-40. Immunoreactive bands were visualized by ECL according to the specifications of the manufacturer (Amersham Pharmacia Biotech).

Two-hybrid System for Protein-Protein Interaction-- The C terminus of dystrophin (amino acids 3194-3685) and regions of alpha -dystrobrevin (amino acids 422-564) and beta -dystrobrevin (amino acids 444-606) were cloned in frame with the DNA-binding domain of GAL4 into the pGBT9 plasmid (pGBT9-DYS, pGBT9-DTNA, and pGBT9-DTNB, respectively), whereas gamma 1-syntrophin (amino acids 19-517) and gamma 2-syntrophin (amino acids 1-539) were cloned in frame with the activating domain of GAL4 into the pGAD424 plasmid (pGAD-G1SYN and pGAD-G2SYN, respectively) (CLONTECH). For gamma 1-syntrophin, a plasmid in which exon 18 is deleted (pGAD-G1SYNDelta 18) was also utilized. In addition, human alpha 1-syntrophin (amino acids 173-505; pGAD-A1SYN) was utilized as a positive control for the interaction with dystrophin and related proteins. The p53 and pSV40 control plasmids were supplied with a kit.

The pGBT9-DYS, pGBT9-DTNA, and pGBT9-DTNB plasmids were cotransformed in the YRG-2 yeast strain, containing two Gal4-inducible reporter genes, HIS3 and lacZ, with pGAD-G1SYN, pGAD-G1SYNDelta 18, pGAD-G2SYN, or pGAD-A1SYN according to the specifications of the manufacturer (CLONTECH). The double transformants were plated onto selective plates lacking tryptophan, leucine, and histidine to show the activation of the Gal4-inducible HIS3 reporter gene through protein-protein interaction. Positive clones were also replica-plated on selective medium and tested for beta -galactosidase activity using the colony lift assay following the directions supplied with the kit obtained from CLONTECH to confirm the interaction through the activation of the second Gal4-inducible reporter gene, lacZ.

GST Pull-down Assay-- Full-length gamma 1- and gamma 2-syntrophins were cloned into the pCT expression vector under the cytomegalovirus promoter and transiently transfected into COS-7 cells by electroporation. After 48-72 h, the cells were washed in PBS, resuspended in lysis buffer (50 mM Tris-HCl (pH 8.0), 200 mM NaCl, 5 mM dithiothreitol, 1 mM EDTA, 1% Triton X-100, 1 mM phenylmethylsulfonyl fluoride, and protease inhibitors), and incubated for 30 min at 4 °C with shaking. The protein extract was clarified by centrifugation at 20,000 × g for 30 min at 4 °C. Then, 100 µl of extract was incubated with 25 µl of GST-dystrophin/dystrobrevin bead-bound fusion proteins and GST-alone bead-bound fusion protein overnight at 4 °C with shaking. After extensive washing with buffer containing 50 mM Tris-HCl (pH 8.0), 100 mM NaCl, 1 mM dithiothreitol, 0.1% Triton X-100, 1 mM phenylmethylsulfonyl fluoride, and protease inhibitors, 25 µl of sample buffer (125 mM Tris-HCl (pH 6.8), 8 M urea, 4% SDS, 100 mM dithiothreitol, and 0.001% bromphenol blue) was added to the beads. After boiling, samples were run on 9% SDS-polyacrylamide gel and analyzed by Western blotting.

Rat Tissues-- Adult Wistar rats (3 months old, 250-300 g) were killed under deep anesthesia (0.1 mg/g sodium barbital), and their brains and spinal cords were quickly dissected out and frozen immediately on dry ice. Cryostat sections 10 µm thick were collected onto Superfrost Plus slides (Erie Scientific, Portsmouth, NH) and stored at -80 °C until processed.

Riboprobe Preparation-- The rat gamma 1- and gamma 2-syntrophin cDNA fragments obtained by RT-PCR were subcloned into the EcoRV site of the pBluescript SK vector. The 701- and 432-nucleotide cRNA probes were transcribed in both the antisense and sense orientations from the properly linearized plasmids, using 20 units of T3 or T7 RNA polymerase (Promega), 30 µM 35S-UTP (1300 Ci/mmol), and 10 mM each unlabeled ATP, CTP, and GTP.

In Situ Hybridization-- In situ hybridization was performed on 10-µm tissue sections from fresh frozen, non-perfused rat brain and spinal cord as described (51, 52) with minor modifications. Briefly, after fixation in 4% paraformaldehyde, sections were treated with 0.5% acetic anhydride in 100 mM triethanolamine (pH 8.0) and prehybridized for 1 h at 55 °C in prehybridization buffer (50% formamide, 750 mM NaCl, 50 mM sodium phosphate buffer (pH 7.0), 10 mM EDTA, 200 µg/ml heparin, 5× Denhardt's solution, and 0.5 mg/ml purified tRNA) containing 10% dextran sulfate and 35S-RNA probe (2 × 108 cpm/ml). After hybridization, sections were treated with 20 µg/ml RNase, washed at high stringency for 1 h at 60 °C, and agitated overnight in 1× SSC. The dehydrated sections were coated with NBT-2 emulsion (Eastman Kodak Co.) and exposed for 2-5 weeks. The autoradiograms were developed, lightly counterstained with methylene blue or hematoxylin and eosin, and examined by dark- and bright-field microscopy. A sense strand probe labeled to the equivalent specific radioactivity of the antisense probe was used on adjacent sections in all experiments to check for background hybridization.

Immunohistochemistry-- Sections were dried at room temperature, fixed in cold acetone, and pretreated with 0.3% H2O2 in PBS to quench the endogenous peroxidase activity; rinsed in PBS; and incubated with 10% normal goat serum and 0.2% Triton X-100 for 60 min to mask nonspecific adsorption sites. Sections were then incubated for 1 h at room temperature with the anti-gamma 1- and anti-gamma 2-syntrophin rabbit polyclonal antibodies (diluted 1:200 in PBS). Omission of the primary antibodies or their replacement by preimmune sera was used for control experiments. After several rinses in PBS, the sections were incubated with biotinylated goat anti-rabbit IgG, washed in PBS, and then incubated with the ABC complex according to the manufacturer's instructions (Vectastain ABC, Vector Labs, Inc.). Peroxidase staining was obtained by incubating the sections in 0.075% 3,3'-diaminobenzidine and 0.002% H2O2 in 50 mM Tris buffer (pH 7.6) for 10 min. In control experiments, when primary antibodies were omitted or replaced by nonimmune sera, the immunoreaction did not take place.

Immunofluorescence of Human Muscle-- Unfixed cryostat sections (5 µm thick) were cut from diagnostic muscle biopsies, air-dried, fixed in cold acetone, preincubated with 10% normal goat serum in PBS for 30 min, and incubated for 1 h at room temperature with a 1:50 dilution of anti-gamma 1- or anti-gamma 2-syntrophin antibody in PBS containing 1% bovine serum albumin. After several rinses in PBS, indirect immunofluorescence was visualized using biotinylated secondary antibodies (1:40) and fluorescein isothiocyanate-labeled streptavidin (1:250) (Amersham Pharmacia Biotech). Sections were covered with a glycerol mount and examined with an Olympus photomicroscope equipped with epifluorescence.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Isolation and Sequence Analysis of Syntrophin cDNAs-- The peptide sequences of human and mouse alpha 1-syntrophin (GenBankTM/EBI Data Bank accession numbers U40571 and U00677, respectively), beta 1-syntrophin (L31529 and U89997, respectively), and beta 2-syntrophin (U40572 and U00678, respectively) were matched using the TBLASTn algorithm with electronic data base sequences, including the subset of ESTs. Two distinct EST groups were retrieved. Each belong to novel cDNAs, having significant amino acid similarity to the three human syntrophins. The former sequence was found in human ESTs H16675, R13432, and R25045, and the latter in human EST Z43606. Clones 49263 and c-1gb01, for the first and second sequences, respectively, derived from an infant brain cDNA library, provided by IMAGE Consortium. These clones were sequenced and used as probes for further screening of human fetal brain and NT2 neuronal precursor cell cDNA libraries. Altogether, 16 clones (eight for each probe) were isolated to confirm and complete the sequence of both cDNAs.

The former cDNA, initially named syn4, is 1898 bp long and includes an open reading frame of 1554 nucleotides (GenBankTM/EBI accession number AJ003030). It encodes a protein of 517 amino acids with a predicted molecular mass of 57,932 Da and a calculated isoelectric point of 6.24. The latter cDNA, initially named syn5, is 1938 bp long and contains an open reading frame of 1620 nucleotides (GenBankTM/EBI accession number AJ003029). It encodes a protein of 539 amino acids with a predicted molecular mass of 60,066 Da and a calculated isoelectric point of 7.59. Some differences have been observed for a few syn4 and syn5 clones. These are likely due to alternative splicing. For both cDNAs, the sequence flanking the first ATG is in accordance with the Kozak consensus for translational start sites (53). In agreement with other investigators, we have renamed syn4 and syn5 as gamma 1-syntrophin and gamma 2-syntrophin, respectively.

Peptide similarity (40-44%) to the human syntrophins spanned the entire open reading frames. Similarity to a Caenorhabditis elegans protein (U49829) is higher (46-52%). The gamma 1- and gamma 2-syntrophins share a 73% amino acid similarity, thus suggesting that the two proteins are much more closely related and probably derived from a common single syntrophin precursor.

Computational Analysis of Protein Sequence-- The syntrophin sequences share distinctive conserved motifs: two PH domains and one PDZ domain, with the first PH domain split into two regions (PH1a and PH1b) by the PDZ domain and its flanking regions (32, 33). In addition, another region has been recognized in the C-terminal 57 amino acids and termed the SU domain (32, 33). There are indications that this domain is involved in dystrophin binding.

We have produced a multiple sequence alignment of all syntrophins using the CLUSTAL W1.7 program (49) (Fig. 1). The gamma 1- and gamma 2-syntrophins are very similar to the other syntrophins in the PDZ domain. The PH domain is not easy to recognize since it includes a series of relatively poorly conserved peptides interspersed with less conserved linker sequences. These may vary from a few amino acids to 100 or more, often containing other functional domains. Nevertheless, the C-terminal 15 or so amino acids contain only an invariant Trp residue, and the six N-terminal residues from this amino acid frequently include two or more negatively charged residues as well as glutamic acid (46). The alignment shows that both the C-terminal Trp residues of the PH1 and PH2 domains are present in gamma 1- and gamma 2-syntrophins (Fig. 1), suggesting that both domains can be conserved.


View larger version (96K):
[in this window]
[in a new window]
 
Fig. 1.   Multiple sequence alignment of the known syntrophins. The alignment includes mouse (MOU-A1SYN; U00677), rabbit (RAB-A1SYN; U01243), and human (HUM-A1SYN; U40571) alpha 1-syntrophin; mouse (MOU-B1SYN; U89997) and human (HUM-B1SYN; I59291) beta 1-syntrophin; mouse (MOU-B2SYN; U00678) and human (HUM-B2SYN; U40572) beta 2-syntrophin; and human gamma 1-syntrophin (HUM-G1SYN) and gamma 2-syntrophin (HUM-G2SYN). We have also considered the T. californica syntrophin (TCA-SYN; U00676) and two proteins of C. elegans similar to syntrophins (CEL-SYN1, Z81072; and CEL-SYN2, U49829). The PDZ, PH, and SU domains are boxed. The arrows indicate the putative conserved Trp residue at the C terminus of PH domains.

The SU domain is less homologous, with only a weak similarity to the other three syntrophins. The proposed secondary structure of the SU domain is composed of three to five beta -sheets separated by as many turns (33). Using the PHDsec algorithm (50), the predicted secondary structure of gamma 1- and gamma 2-syntrophins is mainly arranged into an alpha -helix.

We analyzed gamma 1- and gamma 2-syntrophins using the PROFILESCAN program. A PDZ domain was identified in both proteins (residues 57-140 for gamma 1-syntrophin and residues 73-156 for gamma 2-syntrophin) and only one PH domain, corresponding to the PH2 domain of the other syntrophins (residues 283-390 for gamma 1-syntrophin and residues 296-421 for gamma 2-syntrophin) (Fig. 1). No other domain was found. In addition, we have also identified, in both proteins, an ATP/GTP-binding site motif A (P-loop) (54) (residues 440-448 for gamma 1-syntrophin and residues 471-479 for gamma 2-syntrophin). This motif is a glycine-rich region that typically forms a loop between a beta -strand and an alpha -helix. This loop interacts with one of the phosphate groups of the nucleotide. Many potential phosphorylation sites have also been identified with no clear relationship to the other syntrophins.

Phylogenetic analysis of all syntrophins establishes a common origin of the syntrophins with a early separation into two groups: the first including alpha 1-, beta 1-, and beta 2-syntrophins, and the second including gamma 1- and gamma 2-syntrophins. The two C. elegans syntrophins are final confirmation.

Tissue Distribution of gamma 1- and gamma 2-Syntrophin Expression-- The expression of gamma 1- and gamma 2-syntrophins in human and rat adult tissues was assayed by Northern blotting, using fragments of the respective cDNAs as probes.

Expression of gamma 1-Syntrophin Is Brain-specific in Humans and Rats-- In man, only an ~7.0-kb transcript was observed using a 426-bp cDNA probe encoding the last 126 amino acids (Fig. 2a). Conversely, the rat cDNA probe (701 bp), corresponding to amino acids 29-290 of human gamma 1-syntrophin, hybridized with three equally abundant transcripts of ~2.6, 3.4, and 7.5 kb (Fig. 2b). The different probes may reflect the different expression pattern. The mRNAs are much longer than the coding sequence, and a long 3'-UTR and/or 5'-UTR is probably present. The expression of further gamma 1-syntrophin isoforms most likely originates by alternative splicing. For example, exon 18 is in-frame spliced out in clone 49263, and so is the fourth exon in another gamma 1-syntrophin cDNA clone. Other alternatively spliced products were identified by RT-PCR (data not shown).


View larger version (41K):
[in this window]
[in a new window]
 
Fig. 2.   Distribution of mRNA for gamma 1- and gamma 2-syntrophins in human and rat tissues. In a, a human multiple tissue Northern blot (CLONTECH) was hybridized with a 426-bp cDNA fragment encoding the last 126 amino acids of human gamma 1-syntrophin. The tissues represented in each lane are as follows: lane 1, heart; lane 2, brain; lane 3, placenta; lane 4, lung; lane 5, liver; lane 6, skeletal muscle; lane 7, kidney; lane 8, pancreas. In b and c, a rat multiple tissue Northern blot (Origene) was hybridized with an amplified 702-bp cDNA fragment of rat gamma 1-syntrophin (b), corresponding to the region encoding amino acids 58-290 of human gamma 1-syntrophin, and an amplified 432-bp cDNA fragment of rat gamma 2-syntrophin (c) that encodes amino acids 93-236 of human gamma 2-syntrophin. The tissues represented in each lane are as follows: lane 1, brain; lane 2, heart; lane 3, kidney; lane 4, lung; lane 5, testis; lane 6, skin.

Conversely, gamma 2-syntrophin has a broader but weaker expression. A clearer picture of gamma 2-syntrophin comes from rat Northern blots (Fig. 2c). In addition to brain with two transcripts of ~2.1 and 2.3 kb and a third very weakly hybridizing transcript of 2.5 kb, a mRNA of 2.1 kb was also observed in testis. Weak signals at 0.8, 2.2, and 2.5 kb were also present in kidney and lung, as well as a weaker 1.6-kb transcript in heart.

These different transcripts are probably related to isoforms of this gene. Evidence for this hypothesis comes from cDNA library screening and RT-PCR of human brain cDNA. In particular, we have characterized two isoforms. In the first, exons 3-5, corresponding to the first half of the PDZ domain, are in-frame spliced out; and in exon 9, a putative 5'-donor splicing site at bp 693 leads to in-frame deletion of the last 27 bp of this exon, corresponding to amino acids 830-839. Interestingly, the consensus of the protein kinase C phosphorylation site can be recognized in this fragment. In the second isoform, exons 3-6 are equally in-frame spliced out, and the PDZ domain is nearly entirely eliminated.

Genomic Structure and Chromosomal Mapping-- Genomic library screening and long-range and vectorette PCR were used to determine exon-intron boundaries of these genes. The gamma 1-syntrophin gene (SNTG1) has 19 exons (Table I). The first two exons contain the 5'-UTR, and the first methionine is in the third exon. The gamma 2-syntrophin gene (SNTG2) has at least 17 exons (Table II). The first exon includes the first methionine. For both genes, the termination signal in the last exon is followed by a 3'-UTR colinear with the genomic sequence. The exon structure and splicing sites are conserved in the coding sequences between gamma 1- and gamma 2-syntrophins (Tables I and II), suggesting a common origin.

                              
View this table:
[in this window]
[in a new window]
 
Table I
Genomic organization of gamma 1-syntrophin
For each exon, the sequence at exon-intron boundaries is shown, as well as the length and the corresponding region or domain. The numbers 0, 1, and 2 indicate the splicing phase when the interruption falls before the first, second, or third base of a codon.

                              
View this table:
[in this window]
[in a new window]
 
Table II
Genomic organization of gamma 2-syntrophin
For each exon, the sequence at exon-intron boundaries is shown, as well as the length and the corresponding region or domain. The numbers 0, 1, and 2 indicate the splicing phase when the interruption falls before the first, second, or third base of a codon.

Two methods were employed for chromosomal mapping. For gamma 1-syntrophin, PCR primers, designed from genomic sequences around exons 1 and 19, were used to screen a yeast artificial chromosome library and a radiation hybrid panel (Genebridge 4, Research Genetics). One yeast artificial chromosome clone (856d11) containing the markers AFMB353XD9, D8S589, and D8S1652 (chromosome 8q11) was identified. Radiation hybrid mapping confirmed the chromosomal location at 8q11 between D8S1622 and AFMB353XD9 (4.7 centirays from AFMB353XD9). gamma 2-Syntrophin was mapped to chromosome 2 at p25 between D2S323 and D2S330 (1.7 centirays from D2S323) by radiation hybrid using PCR primers flanking exon 12.

In Vivo and in Vitro Assays of Binding with Dystrophin-- The alpha 1-, beta 1-, and beta 2-syntrophins have been shown to bind dystrophin, utrophin, and dystrobrevins in vitro (34, 35, 39, 40, 55). To verify whether gamma 1- and gamma 2-syntrophins can also bind dystrophin or related proteins, assays of protein-protein interaction were used. In addition, we performed a GST pull-down assay. The C terminus of dystrophin or alpha - or beta -dystrobrevin was fused to glutathione S-transferase protein in the pGEX-2TK plasmid, expressed in E. coli cells, and purified on glutathione-agarose beads. The full-length coding sequences of gamma 1- and gamma 2-syntrophins were then cloned, as sense and antisense, into the pCT plasmid and transfected into COS-7 cells. The protein extracts were incubated with the bead-bound fusion proteins and, after extensive washing, analyzed by Western blotting.

To detect gamma 1- and gamma 2-syntrophins, we used immunopurified rabbit antibodies raised against GST-gamma 1-syntrophin-(195-302) and GST-gamma 2-syntrophin-(209-299) fusion proteins. The gamma 1- and gamma 2-syntrophins were affinity-purified by the GST-dystrophin/dystrobrevin bead-bound fusion proteins, and no signals were observed in control lanes (Fig. 3).


View larger version (15K):
[in this window]
[in a new window]
 
Fig. 3.   In vitro assay of interaction with dystrophin and related proteins by GST pull-down assay. In both Western blots (to the left), the specificity of affinity-purified polyclonal antibody was tested on a panel of GST fusion proteins. COS-7 protein extracts in which the expression of gamma 1-syntrophin (a) or gamma 2-syntrophin (b) had been induced were incubated with GST bead-bound fusion proteins: GST alone (lane A), GST-DYS (lane B), GST-DTNA (lane C), and GST-DTNB (lane D).

The two-hybrid system is a yeast-based genetic assay to detect in vivo protein-protein interaction (56, 57). In the assay, one protein is fused with the DNA-binding domain, and the other with the transcription activation domain of GAL4. Should an interaction occur, the resulting dimer induces reporter gene activation (HIS3 and lacZ). To confirm this interaction in vivo, the dystrophin C terminus (residues 3194-3685) corresponding to exons 66-79 and regions of alpha -dystrobrevin (residues 422-564) and beta -dystrobrevin (residues 444-606), all with the syntrophin-binding site, were fused to the DNA-binding domain of GAL4 in the pGBT9 plasmid (pGBT9-DYS, pGBT9-DTNA, and pGBT9-DTNB, respectively), whereas gamma 1-syntrophin (residues 19-517) and gamma 2-syntrophin (residues 1-539) were fused to the activating domain of GAL4 in the pGAD plasmid (pGAD-G1SYN and pGAD-G2SYN, respectively). In addition, human alpha 1-syntrophin (residues 173-505), fused to the activating domain of GAL4 in the pGAD plasmid (pGAD-A1SYN), was used as a positive control of interaction with dystrophin and related proteins. The pGBT9-DYS, pGBT9-DTNA, and pGBT9-DTNB plasmids were cotransformed in yeast strain YRG-2 with pGAD-G1SYN, pGAD-G2SYN, and pGAD-A1SYN on selective Leu- and Trp- plates and then streaked on His- plates to test the activation of the HIS3 reporter gene.

The gamma 1- and gamma 2-syntrophins interacted with dystrophin in vivo (Fig. 4, a and b). For gamma 1-syntrophin, we also used an isoform without exon 18 (pGAD-G1SYNDelta 18) that includes the ATP/GTP-binding site. This isoform did not interact with dystrophin, confirming that the dystrophin-binding site is located at the C terminus, presumptively in the last 80 amino acids. alpha -Dystrobrevin interacted with gamma 2-syntrophin, but only weakly with gamma 1-syntrophin (Fig. 4c). Conversely, both syntrophins bound to beta -dystrobrevin (Fig. 4d). These findings were confirmed by testing for beta -galactosidase activity (data not shown).


View larger version (48K):
[in this window]
[in a new window]
 
Fig. 4.   In vivo assay of interaction with dystrophin and related proteins using the yeast two-hybrid system. The gamma 1- and gamma 2-syntrophins were tested with dystrophin (a and b) and with alpha - and beta -dystrobrevins, respectively (c and d). In the table, the cotransformed plasmid pairs are indicated for each sector of plates. Dys, dystrophin; DtnA, alpha -dystrobrevin; DtnB, beta -dystrobrevin; Syn, syntrophin.

In Situ Hybridization in Rat Central Nervous System Tissues-- gamma 1- and gamma 2-syntrophin mRNAs were detected by in situ hybridization in all rat central nervous system regions examined; and in particular, they were highly expressed by neuronal cells. The expression of syntrophin transcripts was mainly restricted to cells with neuronal morphology. Hybridization grains for the gamma 1- and gamma 2-syntrophin mRNAs were localized in the perikaryon and proximal portion of the neuronal processes. Strong hybridization signals were localized in the hippocampus, neuron-rich dentate granule cells, and pyramidal cell layers (Fig. 5). Intense labeling was observed in neurons of the cerebral (parietal and frontal) cortex (Fig. 5G). gamma 1- and gamma 2-syntrophin mRNAs were also expressed in the cerebellar cortex, deep cerebellar nuclei, thalamus, and basal ganglia (data not shown). A very strong mRNA signal was present within neurons of both anterior and posterior horns of the spinal cord, whereas a lower signal could be detected in the white matter (Fig. 5, C and E). No specific signal over the background was detectable after hybridization of adjacent sections with the sense strand probe (data not shown). This confirmed the specificity of hybridization. Moreover, RNA studies were concordant with the distribution of the gamma 1- and gamma 2-syntrophin immunoreactivities. Using polyclonal antibodies raised against gamma 1- and gamma 2-syntrophins, we observed reactivities in the same cell populations containing abundant levels of the corresponding mRNAs (Fig. 5, B, D, F, and H), thus confirming that gamma 1- and gamma 2-syntrophin gene products are indeed highly expressed in the central nervous system. The widespread, albeit uneven, distribution of gamma 1- and gamma 2-syntrophin transcripts and proteins throughout different cerebral and spinal areas suggests that gamma 1- and gamma 2-syntrophin genes play an important housekeeping role in neurons.


View larger version (157K):
[in this window]
[in a new window]
 
Fig. 5.   In situ hybridization and immunohistochemistry of rat central nervous system tissues. Shown are dark-field photomicrographs of in situ hybridization analysis of gamma 1-syntrophin (A and C) and gamma 2-syntrophin (E and G) mRNAs compared with gamma 1-syntrophin (B and D) and gamma 2-syntrophin (F and H) immunohistochemistry detected in representative fields of close (not adjacent) tissue sections. A, coronal section of rat hippocampus showing strong signals in neuron-rich dentate granule cells and pyramidal cell layers; B, gamma 1-syntrophin immunoreactivity distribution in the hippocampus; C, gamma 1- and gamma 2-syntrophin mRNAs abundantly expressed in neurons of both ventral and dorsal horns of rat cervical spinal cord (a positive signal is present in the white matter overprojection emerging from the gray matter); D, intense labeling with gamma 1-syntrophin antibody observed over neuron perykarya and in cross-sectioned axons or dendrites; E, gamma 2-syntrophin transcript diffusely expressed in the gray matter of the spinal cord, showing the highest hybridization signal in the ventral horn; F, gamma 2-syntrophin-immunopositive neurons in the ventral horn; G, intense signal for gamma 2-syntrophin mRNA detected in rat cerebral neocortex, particularly in the infragranular layers; H, pyramidal and multipolar neurons of the frontal cortex intensely labeled with anti-gamma 2-syntrophin antibody. Original magnification: ×25 in A and B; ×40 in C, D, G, and H; and ×200 in E and F.

Immunofluorescence of Human Muscle-- No signal was found with anti-gamma 1-syntrophin antibody (Fig. 6A). gamma 2-Syntrophin showed a strong sarcolemmal immunoreactivity in all muscle fibers (Fig. 6B). In DMD patients with absence of dystrophin, gamma 2-syntrophin was absent or severely reduced (Fig. 6C); In contrast, a normal plasmalemmal signal was observed in patients with neurogenic atrophy (Fig. 6D). Upon immunofluorescence, gamma 2-syntrophin was not selectively localized at the neuromuscular junctions and was present on the membrane of cardiomyocytes in two biopsy specimens (data not shown).


View larger version (55K):
[in this window]
[in a new window]
 
Fig. 6.   Immunofluorescence of human muscle. Shown is the gamma 1-syntrophin (A) and gamma 2-syntrophin (B-D) immunofluorescence of normal muscle (A and B) and of muscle from patients with DMD (C) and neurogenic atrophy (D). Original magnification: ×400 in A and D; and ×200 in B and C.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Originally identified in postsynaptic membranes of T. californica (29), syntrophins are intracellular peripheral membrane proteins of ~58 kDa that, in man and mouse, exist in three highly conserved but distinct isoforms (alpha 1, beta 1, and beta 2) encoded by different genes (30, 31, 33). The name "syntrophin" was introduced to indicate that this group of proteins accompanies dystrophin. Further studies have demonstrated that syntrophins also accompany all the other proteins of the dystrophin family such as utrophin (dystrophin-related protein 1) (35), dystrophin-related protein 2, and dystrobrevins (alpha  and beta ) (37, 38). Binding is mediated by amino acid sequences that are homologous to the cysteine-rich domain and C-terminal region of dystrophin encoded by exon 74 (34, 39, 40).

The role of syntrophins and their requirement for muscle and nerve cell function are still obscure. To date, no human disease has been associated with a syntrophin gene mutation. Likewise, no gross histological changes in the skeletal muscle of alpha 1-syntrophin knockout mouse (the first syntrophin-deficient animal model) have been reported (58). This may be due to a redundancy of the genes of the syntrophin family. The lack of function of one gene could be replaced by other members of the family, coexpressed in the same tissues. In man, the alpha 1-syntrophin transcript is predominantly expressed in skeletal and cardiac muscle, whereas the beta 1- and beta 2-syntrophin transcripts are expressed in a wide variety of tissues (31, 33, 37). In addition, histochemical studies with specific antibodies revealed that the three syntrophins are all present at the neuromuscular junction. alpha 1-Syntrophin is also found at the sarcolemma, whereas beta 1-syntrophin occurs at the sarcolemma of fast twitch muscle fibers (37). We indicate here that the syntrophin gene family should include at least two other members, which are less related to the primary sequences of known syntrophins, but retain the property of dystrophin binding. gamma 1- and gamma 2-syntrophins should be considered a separate entity because of their relatedness (73% similarity), the common C. elegans ancestor gene, and the genomic organization. In particular, these two genes are split into 17-19 exons by long introns at corresponding positions that are different from the exon-intron boundaries found in the other syntrophins. In addition, we observed a complex pattern of alternatively spliced products, with the presence, at least for gamma 2-syntrophin, of both translated and nonfunctional transcripts.

Expression data indicate that gamma 1-syntrophin is restricted to neurons. gamma 2-Syntrophin has a broader expression and a more complex pattern of splicing and is presumably included in the dystrophin-associated complex beneath the muscle membrane at the sarcolemma. In fact, some DMD patients show a secondary reduction of gamma 2-syntrophin protein expression.

The ability of gamma 1- and gamma 2-syntrophins to bind dystrophin and dystrobrevins (alpha  and beta ) has been confirmed in vivo and in vitro. Binding is mediated by the last 80 amino acids, a region with weak similarity to the SU domain, the putative dystrophin-binding site. The homologous cysteine-rich domain and C-terminal region of dystrophin and related proteins include the syntrophin-binding site and several potential binding domains (59, 60). In particular, a coiled-coil motif, flanking the syntrophin-binding site, links dystrophin to the same motif in the C terminus of dystrobrevin. Therefore, dystrophin interacts with dystrophin-glycoprotein complexes via the cysteine-rich domain and heterodimerizes with dystrobrevins via the coiled-coil motif (61). Together, dystrophin and dystrobrevin can recruit two syntrophins. This model seems to be confirmed by the observation that dystrophin complexes are highly enriched in alpha 1- and beta 1-syntrophins, whereas utrophin complexes contain mostly beta 1- and beta 2-syntrophins (37). Different pairings are possible between the syntrophins: gamma 1- and gamma 2-syntrophins increase the possible combinations in brain.

DMD and Becker muscular dystrophy patients with point mutations or deletions localized in the 3'-region of the dystrophin gene in addition to the progressive muscle wasting show a higher incidence of mental retardation, with learning disorders and speech difficulties (62). In contrast, mutations localized in other parts of the gene are usually not associated with mental retardation. There is no explanation for this clinical observation because dystrophin is absent or severely reduced in DMD patients, regardless of where the primary nonsense mutation occurs. The presence of additional promoters located in certain dystrophin gene introns could still generate functional mini-dystrophin 3'-transcripts (apodystrophins), unless the mutation does not directly involve the 3'-exons. The latter part of the dystrophin gene encodes the region endowed with the dystroglycan-binding site (exon 65) and the syntrophin-binding site (exons 73-74).

In the brain, gamma 1- and gamma 2-syntrophins as well as beta -dystrobrevin can bind dystrophin isoforms Dp71 and Dp140 (63). In common with dystrophin and beta -dystrobrevin, gamma 1- and gamma 2-syntrophins are found in the cortex and hippocampal formation. These data provide evidence that the composition of the dystrophin-associated protein complex in the brain differs from that in muscle (64). A mouse transgene overexpressing apodystrophin-1/Dp71 (exons 63-79) in dystrophin-deficient animals (mdx mice) could not restore the normal muscle phenotype (65, 66). This suggests that this dystrophin fragment alone has no influence on the muscle disease progression. It is possible that the presence of an intact C-terminal fragment could be important for the associated mental disorders. The apodystrophin-dystroglycan complex in the central nervous system can bind the gamma 1- and gamma 2-syntrophins. Further studies are needed to determine the role of these novel syntrophins in neuron signaling processes and whether their concomitant lack affects learning.

    ACKNOWLEDGEMENTS

We are indebted to J. Sepe for review of the manuscript. We thank the Yeast Artificial Chromosome Screening Center (Ospedale San Raffaele, Milano, Italy) and the Telethon Institute of Genetics and Medicine for technical support.

    FOOTNOTES

* This work was supported in part by Telethon-Italy and Ministero delle'Università e della Ricerca Scientifica e Tecnologica.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

The nucleotide sequence(s) reported in this paper has been submitted to the GenBankTM/EMBL Data Bank with accession number(s) AJ003030 and AJ003029.

|| Supported in part by a grant from the Ministero Università e Ricerca Scientifica.

Dagger Dagger To whom correspondence should be addressed: Ist. di Patologia Generale e Oncologia, Facoltà di Medicina, Seconda Università degli Studi di Napoli, Larghetto S. Aniello a Caponapoli 2, 80138 Napoli, Italy. Tel.: 39081-5665675; Fax: 39081-5665695; E-mail: vincenzo.nigro@unina2.it.

Published, JBC Papers in Press, March 16, 2000, DOI 10.1074/jbc.M000439200

    ABBREVIATIONS

The abbreviations used are: DMD, Duchenne muscular dystrophy; PH, pleckstrin homology; SU, syntrophin unique; EST, expressed sequence tag; bp, base pair(s); RT-PCR, reverse transcription-polymerase chain reaction; GST, glutathione S-transferase; PBS, phosphate-buffered saline; kb, kilobase pair(s); PZD, postsynaptic density 95/discs large/zona occludens-1; UTR, untranslated region.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Hoffman, E. P., Brown, R. H., Jr., and Kunkel, L. M. (1987) Cell 51, 919-928
2. Emery, A. E. H. (1993) Duchenne Muscular Dystrophy , Oxford University Press, Oxford, and references therein
3. Ervasti, J. M., and Campbell, K. P. (1991) Cell 66, 1121-1131
4. Yamamoto, H., Hagiwara, Y., Mizuno, Y., Yoshida, M., and Ozawa, E. (1993) J. Biochem. (Tokyo) 114, 132-139
5. Yoshida, M., Suzuki, A., Yamamoto, H., Noguchi, S., Mizuno, Y., and Ozawa, E. (1994) Eur. J. Biochem. 222, 1055-1061
6. Koenig, M., Monaco, A. P., and Kunkel, L. M. (1988) Cell 53, 219-226
7. Ibraghimov-Beskrovnaya, O., Ervasti, J. M., Leveille, C. J., Slaughter, C. A., Sernett, S. W., and Campbell, K. P. (1992) Nature 355, 696-702
8. Campanelli, J. T., Roberds, S. L., Campbell, K. P., and Scheller, R. H. (1994) Cell 77, 663-674
9. Gee, S. H., Montanaro, F., Lindenbaum, M. H., and Carbonetto, S. (1994) Cell 77, 675-686
10. Hopf, C., and Hoch, W. (1996) J. Biol. Chem. 271, 5231-5236
11. Henry, M. D., and Campbell, K. P. (1998) Cell 95, 859-870
12. Crosbie, R. H., Heighway, J., Venzke, D. P., Lee, J. C., and Campbell, K. P. (1997) J. Biol. Chem. 272, 31221-31224
13. Roberds, S. L., Leturcq, F., Allamand, V., Piccolo, F., Jeanpierre, M., Anderson, R. D., Lim, L. E., Lee, J. C., Tome, F. M., Romero, N. B., Fardeau, M., Beckmann, J. S., Kaplan, J.-C., and Campbell, K. P. (1994) Cell 78, 625-633
14. McNally, E. M., Yoshida, M., Mizuno, Y., Ozawa, E., and Kunkel, L. M. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 9690-9694
15. Bonnemann, C. G., Modi, R., Noguchi, S., Mizuno, Y., Yoshida, M., Gussoni, E., McNally, E. M., Duggan, D. J., Angelini, C., and Hoffman, E. P. (1995) Nat. Genet. 11, 266-273
16. Lim, L. E., Duclos, F., Broux, O., Bourg, N., Sunada, Y., Allamand, V., Meyer, J., Richard, I., Moomaw, C., Slaughter, C., Tomé, F. M. S., Fardeau, M., Jackson, C. E., Beckmann, J. S., and Campbell, K. P. (1995) Nat. Genet. 11, 257-265
17. Noguchi, S., McNally, E. M., Ben Othmane, K., Hagiwara, Y., Mizuno, Y., Yoshida, M., Yamamoto, H., Bonnemann, C. G., Gussoni, E., Denton, P. H., Kyriakides, T., Middleton, L., Hentati, F., Ben Hamida, M., Nonaka, I., Vance, J. M., Kunkel, L. M., and Ozawa, E. (1995) Science 270, 819-822
18. Nigro, V., Piluso, G., Belsito, A., Politano, L., Puca, A. A., Papparella, S., Rossi, E., Viglietto, G., Esposito, M. G., Abbondanza, C., Medici, N., Molinari, A. M., Nigro, G., and Puca, G. A. (1996) Hum. Mol. Genet. 5, 1179-1186
19. Helbling-Leclerc, A., Zhang, X., Topaloglu, H., Cruaud, C., Tesson, F., Weissenbach, J., Tome, F. M., Schwartz, K., Fardeau, M., Tryggvason, K., and Guicheney, P. (1995) Nat. Genet. 11, 216-218
20. Piccolo, F., Roberds, S. L., Jeanpierre, M., Leturcq, F., Azibi, K., Beldjord, C., Carrie, A., Recan, D., Chaouch, M., Reghis, A., El Kerch, F., Sefiani, A., Voit, T., Merlini, L., Collin, H., Eymard, B., Beckmann, J. S., Romero, N. B., Tomé, F. M. S., Fardeau, M., Campbell, K. P., and Kaplan, J.-C. (1995) Nat. Genet. 10, 243-245
21. Nigro, V., de Sa Moreira, E., Piluso, G., Vainzof, M., Belsito, A., Politano, L., Puca, A. A., Passos-Bueno, M. R., and Zatz, M. (1996) Nat. Genet. 14, 195-198
22. Minetti, C., Sotgia, F., Bruno, C., Scartezzini, P., Broda, P., Bado, M., Masetti, E., Mazzocco, M., Egeo, A., Donati, M. A., Volonte, D., Galbiati, F., Cordone, G., Bricarelli, F. D., Lisanti, M. P., and Zara, F. (1998) Nat. Genet. 18, 365-368
23. McNally, E. M., de Sa Moreira, E., Duggan, D. J., Bonnemann, C. G., Lisanti, M. P., Lidov, H. G. W., Vainzof, M., Passos-Bueno, M. R., Hoffman, E. P., Zatz, M., and Kunkel, L. M. (1998) Hum. Mol. Genet. 7, 871-877
24. Nigro, V., Okazaki, Y., Belsito, A., Piluso, G., Matsuda, Y., Politano, L., Nigro, G., Ventura, C., Abbondanza, C., Molinari, A. M., Acampora, D., Nishimura, M., Hayashizaki, Y., and Puca, G. A. (1997) Hum. Mol. Genet. 6, 601-607
25. Duclos, F., Straub, V., Moore, S. A., Venzke, D. P., Hrstka, R. F., Crosbie, R. H., Durbeej, M., Lebakken, C. S., Ettinger, A. J., van der Meulen, J., Holt, K. H., Lim, L. E., Sanes, J. R., Davidson, B. L., Faulkner, J. A., Williamson, R., and Campbell, K. P. (1998) J. Cell Biol. 142, 1461-1471
26. Araishi, K., Sasaoka, T., Imamura, M., Noguchi, S., Hama, H., Wakabayashi, E., Yoshida, M., Hori, T., and Ozawa, E. (1999) Hum. Mol. Genet. 8, 1589-1598
27. Hack, A. A., Ly, C. T., Jiang, F., Clendenin, C. J., Sigrist, K. S., Wollmann, R. L., and McNally, E. M. (1998) J. Cell Biol. 142, 1279-1287
28. Coral-Vazquez, R., Cohn, R. D., Moore, S. A., Hill, J. A., Weiss, R. M., Davisson, R. L., Straub, V., Barresi, R., Bansal, D., Hrstka, R. F., Williamson, R., and Campbell, K. P. (1999) Cell 98, 465-474
29. Froehner, S. C., Murnane, A. A., Tobler, M., Peng, H. B., and Sealock, R. (1987) J. Cell Biol. 104, 1633-1646
30. Adams, M. E., Butler, M. H., Dwyer, T. M., Peters, M. F., Murnane, A. A., and Froehner, S. C. (1993) Neuron 11, 531-540
31. Ahn, A. H., Yoshida, M., Anderson, M. S., Feener, C. A., Selig, S., Hagiwara, Y., Ozawa, E., and Kunkel, L. M. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 4446-4450
32. Adams, M. E., Dwyer, T. M., Dowler, L. L., White, R. A., and Froehner, S. C. (1995) J. Biol. Chem. 270, 25859-25865
33. Ahn, A. H., Freener, C. A., Gussoni, E., Yoshida, M., Ozawa, E., and Kunkel, L. M. (1996) J. Biol. Chem. 271, 2724-2730
34. Ahn, A. H., and Kunkel, L. M. (1995) J. Cell Biol. 128, 363-371
35. Kramarcy, N. R., Vidal, A., Froehner, S. C., and Sealock, R. (1994) J. Biol. Chem. 269, 2870-2876
36. Blake, D. J., Nawrotzki, R., Peters, M. F., Froehner, S. C., and Davies, K. E. (1996) J. Biol. Chem. 271, 7802-7810
37. Peters, M. F., Adams, M. E., and Froehner, S. C. (1997) J. Cell Biol. 138, 81-93